Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceutical Drug Discovery & Development (Miscellaneous)
Enlight Biosciences

Entrega, Inc.

Parents

Biologic drugs (biologics), such as insulin and antibodies, represent over $120 Billion in annual revenues and address major medical needs in areas such as cancer and inflammatory disease.
Dr Robert Langer, Phd, Germeshausen Professor of Chemical & Biomedical Engineering, David H. Koch Institute, MIT (2026)
Entrega will receive undisclosed payments including upfront and research milestone payments.
Entrega will remain independent and retain all rights to the platform technology.
Entrega will use its unique spatially-directed proprietary drug delivery platform to create orally bioavailable formulations of several of the biologic drugs of Enlight's pharmaceutical industry partners
However, most biologics need to be delivered by injection, which leads to challenges in compliance and effectiveness.
The ability to deliver biologics orally would address a significant unmet need for patients around the world.